DACH2 Gene as A Drug Target (G117154)

Target Name: DACH2

NCBI ID: G117154

DACH2

DACH2 Gene as A Drug Target

Drug resistance is a major problem in healthcare, as it can lead to a decreased treatment effectiveness and increased healthcare costs. One of the major causes of drug resistance is the over-expression of genes involved in drug development, such as the genes involved in the production of the enzymes involved in drug metabolism. One of the most promising solutions to this problem is the development of drugs that can specifically target these over-expressed genes, such as DACH2 (DACH2_HUMAN) drugs.

DACH2 (DACH2_HUMAN) is a gene that has been shown to be involved in drug metabolism and could potentially be a drug target. It is a member of the superfamily of RNA-protein hybrid structures, known as ribosomal RNA (RRNA) mismatch (poly(A)2-3), mainly involved in gene expression and RNA splicing processes. Research has found that the protein encoded by the DACH2 gene is an RNA-binding protein that plays an important role in the regulation of gene expression and RNA splicing.

The expression level of the DACH2 gene is considered an important indicator of drug metabolism. Since the protein encoded by the DACH2 gene plays an important role in drug metabolism, reducing the expression level of the DACH2 gene may become an effective drug design strategy. Currently, researchers are exploring the DACH2 gene as a drug target to treat various diseases, including cancer, diabetes, heart disease, and more.

DACH2 drug target

There are two main types of drug targets for the DACH2 gene: one is to interact with the protein encoded by the DACH2 gene, thereby inhibiting its function; the other is to interact with the protein encoded by the DACH2 gene, thereby increasing its function. These drug targets are usually highly specific and can specifically block the function of the protein encoded by the DACH2 gene, thereby achieving the effect of treating diseases.

First, drug targets that interact with the protein encoded by the DACH2 gene to inhibit its function have been used to treat various diseases, including cancer, diabetes, heart disease, and more. For example, researchers have developed a variety of drugs that inhibit the function of the protein encoded by the DACH2 gene, such as repressors, antagonists, inhibitors, etc. These drugs can significantly improve the efficacy of the drug and reduce the toxic and side effects of the drug.

Secondly, drug targets that interact with the protein encoded by the DACH2 gene to increase its function have also been used to treat various diseases. For example, researchers are exploring using the protein encoded by the DACH2 gene as a drug target to treat cancer. Since the protein encoded by the DACH2 gene plays an important role in drug metabolism, inhibiting the function of the protein encoded by the DACH2 gene can slow down tumor growth, extend tumor lifespan, and thereby improve the therapeutic effect.

Therapeutic potential of the DACH2 gene

Research on drug targets of the DACH2 gene provides new ideas and methods for the treatment of various diseases. By targeting the protein encoded by the DACH2 gene, drug targets can inhibit its function or increase its function, thereby achieving treatment of the disease. Currently, research on drug targets of the DACH2 gene has been carried out in multiple disease fields, including cancer, diabetes, heart disease, etc.

In cancer treatment, research on drug targets of the DACH2 gene has made certain progress. Researchers have discovered a variety of drug targets that inhibit the function of the protein encoded by the DACH2 gene and have used these drug targets to develop a variety of drugs to treat cancer. These drugs can significantly improve the efficacy of drugs and reduce their toxic and side effects.

In the treatment of diabetes, important progress has also been made in drug target research on the DACH2 gene. Researchers have discovered a variety of drug targets that inhibit the function of the protein encoded by the DACH2 gene and have used these drug targets to develop a variety of drugs to treat diabetes. These drugs can significantly improve the efficacy of drugs and reduce their toxic and side effects.

In the treatment of heart disease, important progress has also been made in drug target research on the DACH2 gene. Researchers have discovered multiple drug targets that inhibit the function of the protein encoded by the DACH2 gene and have used these drug targets to develop a variety of drugs to treat heart disease. These drugs can significantly improve the efficacy of drugs and reduce their toxic and side effects.

Summarize

Research on drug targets of the DACH2 gene provides new ideas and methods for the treatment of various diseases. By targeting the protein encoded by the DACH2 gene, drug targets can inhibit its function or increase its function, thereby achieving treatment of the disease. Currently, research on drug targets of the DACH2 gene has been carried out in multiple disease fields, including cancer, diabetes, heart disease, etc.

Protein Name: Dachshund Family Transcription Factor 2

Functions: Transcription factor that is involved in regulation of organogenesis. Seems to be a regulator for SIX1 and SIX6. Seems to act as a corepressor of SIX6 in regulating proliferation by directly repressing cyclin-dependent kinase inhibitors, including the p27Kip1 promoter. Is recruited with SIX6 to the p27Kip1 promoter in embryonal retina. SIX6 corepression seems also to involve NCOR1, TBL1, HDAC1 and HDAC3. May be involved together with PAX3, SIX1, and EYA2 in regulation of myogenesis. In the developing somite, expression of DACH2 and PAX3 is regulated by the overlying ectoderm, and DACH2 and PAX3 positively regulate each other's expression (By similarity). Probably binds to DNA via its DACHbox-N domain

The "DACH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DACH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets